Drugs / pCCLCHIM-p47
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06253507 | Jun 2024 → Mar 2027 expected | autosomal recessive disease, chronic granulomatous disease | National Institute of Allergy and Infectious Diseases (NIAID) | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pCCLCHIM-p47 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06253507 ↗ |
| Action | Restore | “the participant s stem cells will be modified in a laboratory to add the gene they are missing.” NCT06253507 ↗ |